Austrian MATAO trial for newly diagnosed Ovarian Cancer
MATAO-A clinical phase III trial on the use of letrozole maintenance therapy for newly diagnosed advanced ovarian, fallopian tube or peritoneal cancers.
MATAO- MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial including LOGOS (LOw Grade Ovarian cancer Sub-study) (ENGOT-ov54/Swiss-GO-2)
Are you just diagnosed with or does your patient belong to this group with newly diagnosed ovarian, fallopian tube or peritoneal cancer, and would you or your patient like to participate in this study?
Until beginning of July 2022, already 79 patients have been randomized in Switzerland and with the upcoming opening of more Sites in Austria, we more than excited to welcome even more patients in the trial.
The MATAO trial as a whole is supported by peer-reviewed grants and funding from:
Stiftung Fürstlicher Kommerzienrat Guido Feger
Reliable Cancer Therapies (Anticancer Fund)
AGO Studiengruppe e.V
(kindly funds this study by providing the drug and placebo for this study and the transport to the CMO free of charge)